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Some closely related human leukocyte antigen (HLA) alleles are associated with variable
clinical outcomes following HIV-1 infection despite presenting the same viral epitopes.
Mechanisms underlying these differences remain unclear but may be due to intrinsic char-
acteristics of the HLA alleles or responding T cell repertoires. Here we examine CD8+ T cell
responses against the immunodominant HIV-1 Gag epitope TL9 (TPQDLNTML180–188) in the
context of the protective allele B*81:01 and the less protective allele B*42:01. We observe a
population of dual-reactive T cells that recognize TL9 presented by both B*81:01 and B*42:01
in individuals lacking one allele. The presence of dual-reactive T cells is associated with lower
plasma viremia, suggesting a clinical beneﬁt. In B*42:01 expressing individuals, the dual-
reactive phenotype deﬁnes public T cell receptor (TCR) clones that recognize a wider range
of TL9 escape variants, consistent with enhanced control of viral infection through contain-
ment of HIV-1 sequence adaptation.
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The rate of clinical progression following human immuno-deﬁciency virus type 1 (HIV-1) infection is variable, withrare individuals maintaining plasma viral loads below 50
RNA copies mL−1 in the absence of therapy1,2. Host and viral
mechanisms associated with relative control of infection indicate
that the ability of HIV-1 to adapt to a new host is a critical
determinant of pathogenesis3,4. Multiple lines of evidence support
the central role of CD8+ T cells in this process5–7. Expression of
certain class I human leukocyte antigen (HLA) alleles, particularly
at the HLA-B locus8,9, is associated with lower plasma viral loads,
higher CD4+ T cell counts and delayed onset of AIDS10,11.
Interaction between CD8+ T cells and viral peptide epitopes
presented on HLA determines breadth and other characteristics
of the antiviral response12,13, while rapid development of viral
mutations in targeted epitopes facilitates evasion from host
immunity3,14,15. CD8+ T cells that target epitopes derived from
p24 Gag are associated with better control16,17, likely due to their
relative immunodominance and greater ﬁtness constraints on
this major viral structural protein15,18–20.
Recognition of a peptide/HLA (pHLA) ligand by a CD8+ T cell
is determined by the sequence and functional characteristics of its
T cell receptor (TCR)21,22. The exceptional diversity of the TCR
repertoire, generated by somatic recombination of variable (V),
diversity (D), and joining (J) gene segments, junctional mod-
iﬁcations, and differential pairing of α and β chains, has profound
implications for immune coverage23. In addition to deﬁning
antigen speciﬁcity, TCR afﬁnity for pHLA can dictate the strength
of intracellular signaling events that modulate T cell effector
functions, including cytotoxicity and proliferative capacity24.
Characteristics of TCR clonotypes that contribute most effectively
to CD8+ T cell-mediated control of HIV-1 infection are largely
unknown, since data linking individual TCR sequences with
measures of antiviral function remains limited. In previous
studies of p24 Gag epitopes TW10 (TSTLQEQIGW240–249) and
KK10 (KRWIILGLNK263–272), presented on protective HLA
alleles B*57:01 and B*27:05, respectively, CD8+ T cell clones
displaying higher functional avidity or greater ability to cross-
recognize epitope variants were shown to have enhanced antiviral
activity25–28. In the case of B*27-KK10, public TCR clonotypes,
deﬁned as having identical (or nearly identical) TCR β sequences
in the antigen-speciﬁc repertoire of at least two unrelated
individuals22,29, displaying high avidity against the consensus
epitope were also associated with a more effective T cell
response28,30.
Following infection with HIV-1 subtype C strains that are
prevalent in sub-Saharan Africa, expression of HLA allele B*81:01
is associated with improved clinical outcomes9,31, while the
genetically-related allele B*42:01 is less protective16,31–36. Both
alleles belong to the HLA B7 supertype37,38 and present similar
viral peptides, including the immunodominant p24 Gag epitope
TL9 (TPQDLNTML180–188)34,39–42. The magnitude of the TL9
response has been associated with lower plasma viremia and
improved clinical outcome in the case of B*81:0143. TL9 is located
on helix 3 of the p24 protein, which is critical to form the mature
viral capsid. Circulating subtype C strains display >99% sequence
identity at all TL9 residues except positions 3 (88.5%) and 7
(93.5%) (HIV Databases; www.hiv.lanl.gov). Positions 3 and 7 are
the principal sites for viral escape from CD8+ T cell
pressure3,31,40,41; however, mutations at these residues also
impair ﬁtness44, indicating that HIV-1 adaptation at TL9 must
balance these counteracting pressures. Structural studies indicate
that the TL9 residues exposed to T cells differ in its bound
conformations with B*81:01 and B*42:0145, and some evidence
suggests that enhanced antiviral T cell function is related to
distinct TCR sequences elicited in the context of B*81:0140. These
observations are consistent with delayed viral escape in B*81:01
expressing individuals compared to B*42:01 expressing indivi-
duals31 and selection of TL9 escape mutations by B*81:01 that
tend to be more difﬁcult to compensate for44. An improved
understanding of clonotypic differences among CD8+ T cells
responding to TL9 could highlight features that contribute to
HIV-1 control in the context of B*81:01 and B*42:01.
Here we investigate the mechanisms associated with immune-
mediated control of HIV-1 subtype C infection by examining the
CD8+ T cell response to the immunodominant p24 Gag epitope
TL9 in virus-infected individuals expressing HLA B*81:01 or
B*42:01 alleles. We identify a subset of T cells that recognize TL9
epitope presented on both B*81:01 and B*42:01 alleles, despite
individuals lacking one allele. The presence of a dual-reactive T
cell population is associated with lower plasma viral loads after
controlling for differences in HLA expression. Notably, the dual-
reactive population in B*42:01 expressing individuals is domi-
nated by several public TCR clonotypes that encoded TRBV12-3.
In contrast, while mono- and dual-reactive populations in
B*81:01 expressing individuals are enriched for TRBV12-3 usage,
no public clonotypes are observed. Comprehensive in vitro
functional analyses of selected TCR clones demonstrated that
B*81:01-derived clones and public dual-reactive B*42:01-derived
clones display greater ability to cross-recognize HIV-1 Gag TL9
escape pathways compare to mono-reactive TCR clones isolated
from B*42:01 expressing individuals. These results illustrate a
use of HLA tetramers and in vitro functional assays to identify
and characterize TCR clonotypes that display enhanced ability
to recognize a rapidly evolving HIV-1 infection.
Results
Characterizing CD8+ T cell responses in study participants.
Population-level studies have demonstrated that HLA-B*81:01
is associated with better control of HIV-1 subtype C infection
than the closely related allele B*42:013,9; however, mechanisms
to explain this remain unclear. To examine this, we recruited
21 treatment-naive HIV-infected individuals expressing B*81:01
(n= 9), B*42:01 (n= 11), or both alleles (n= 1) from Durban,
South Africa. Individuals co-expressing other protective class I
HLA alleles (namely B*57:03, B*58:01, and B*39:01) were exclu-
ded from this study. The clinical characteristics and class I HLA
genotypes of participants are shown in Table 1 and 2, respec-
tively. Consistent with prior reports40,46,47, we observed that
untreated B*81:01 expressing individuals displayed lower plasma
viral loads (median 3.38 log10 RNA copies ml−1 [IQR 2.36–3.99])
compared to untreated B*42:01 expressing individuals (4.15 log10
RNA copies ml−1 [IQR 3.40–4.84]) (p= 0.03, Mann–Whitney U-
test) (Fig. 1a). The difference in CD4 counts between groups was
not statistically signiﬁcant (median 625 cells µl−1 in B*81:01 vs.
555 cells µl−1 in B*42:01; p= 0.14, Mann–Whitney U-test). While
the individual who co-expressed HLA-B*81:01 and B*42:01 alleles
was not included in our analysis of clinical correlations, this
participant displayed the lowest plasma viral load (2.11 log10
RNA copies ml−1) and highest CD4 count (1002 cells µl−1).
Immune targeting of dominant CD8+ T cell epitopes
contributes to long-term suppression of HIV-1 viremia48–50.
The p24 Gag-derived epitope TL9 is immunodominant in both
B*81:01 and B*42:01 expressing individuals39,40, and the
magnitude of the TL9 response has been associated with
improved clinical outcome in the context of B*81:0143. To
characterize the TL9 response in our cohort, we quantiﬁed
antigen-speciﬁc CD8+ T cells using B*81:01 and B*42:01
tetramers. We observed no difference in the frequency of
tetramer+ CD8+ T cells between individuals expressing B*81:01
(median 2.08%) compared to B*42:01 (1.14%) (p= 0.50;
Student’s T test) (Fig. 1b). Notably, intra-patient comparison of
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responses in either B*81:01 or B*42:01 participants showed that
TL9 was the most dominant response compared to other
responses (p= <0.0001, Student’s T test) by both tetramer
staining and ELISPOT (Supplementary Fig. 1A–C and Supple-
mentary Table 1). These data are consistent with previous
studies40,45. The proportion of TL9-speciﬁc CD8+ T cells
expressing IFN-γ following peptide stimulation was also not
signiﬁcantly different between individuals expressing B*81:01
(median 47%) and B*42:01 (27%) (p= 0.09, Student’s T test)
(Fig. 1c); however, the observed trend in favor of B*81:01
participants is consistent with prior work describing moderately
higher TL9-speciﬁc IFN-γ secretion and higher functional avidity
in the context of B*81:0140.
Dual HLA reactivity is associated with lower viral load. To
investigate if there were any qualitative differences in TL9-speciﬁc
CD8+ T cells restricted by these two HLA alleles, we ﬁrst made a
direct comparison between antigen-speciﬁc T cells in the indivi-
dual who co-expressed B*81:01 and B*42:01. Intriguingly, when
we double-stained cells from this individual with both HLA tet-
ramers, we observed a dominant T cell subset that was labeled
using the B*81:01-TL9 tetramer as well as a secondary subset that
was labeled by both B*81:01-TL9 and B*42:01-TL9 tetramers,
which we will refer to as the dual-reactive population (Fig. 1d).
To explore whether the dual-reactive T cell population was
unique to this individual, we re-examined all study participants
using both class I HLA tetramers. We observed dual-reactive TL9
responses in the majority of participants, indicating that a subset
of CD8+ T cells elicited in the context of both B*81:01 and
B*42:01 could cross-recognize TL9 bound to the other class I
HLA allele, even when it was not expressed by the host.
Representative results for two individuals are also shown in
Fig. 1d. The dual-reactive population was seen more frequently in
individuals expressing B*81:01 (7 of 9; 78%) compared to B*42:01
(5 of 11; 46%) (Fig. 1e), but this difference was not statistically
signiﬁcant (p= 0.19, Student’s T test). While CD8+ T cell
promiscuity is frequently observed toward peptide variants
presented on the same HLA allele, we know of only one prior
report that described CD8+ T cell cross-reactivity to the same
peptide presented on two different class I HLA alleles51. In a
multivariable linear regression model, we identiﬁed dual-
reactivity, but not HLA, as a signiﬁcant independent predictor
of lower plasma viral load in our participants (p= 0.02) (Fig. 1f),
suggesting that this T cell phenotype is associated with a clinical
beneﬁt. We therefore hypothesized that features associated with
dual-reactive CD8+ T cells could provide insight into mechan-
isms of HIV-1 control.
Constrained Vβ genes in B*42-derived dual-reactive TCR. The
ability of dual-reactive CD8+ T cells to recognize TL9 bound to
different, albeit related, class I HLA alleles suggested that they
harbored distinct characteristics. Since individual TCR clonotypes
have been associated with improved control of HIV-126–28,52–55,
we analyzed the TCR repertoire found in mono- and dual-
reactive TL9-speciﬁc T cells. First, we investigated TCR β
expression using ﬂow cytometry by co-staining PBMC with
B*81:01- and B*42:01-TL9 tetramers plus a cocktail of Vβ-speciﬁc
antibodies. Representative results for one B*42:01 expressing
individual are shown in Fig. 2a. Consistent with prior studies that
described a high frequency of TRBV12-3 gene usage among
TL9-speciﬁc T cells40,41, we observed that both mono- and dual-
reactive T cells from B*81:01 expressing individuals were highly
enriched for Vβ 12-3/12-4 (Fig. 2b). In contrast, while mono-
reactive T cells from B*42:01 individuals expressed multiple Vβ
families, the dual-reactive T cells from these individuals were
highly enriched for Vβ 12-3/12-4 (Fig. 2c). These results sug-
gested that TCR clonotypes expressed by dual-reactive CD8+
T cells elicited in the context of HLA B*42:01 shared distinct
features with T cells that dominated TL9 responses elicited by
the more protective B*81:01 allele. To conﬁrm these observations,
we sorted mono- and dual-reactive T cells using FACS and
generated separate TL9-speciﬁc cell lines. Similar Vβ staining
proﬁles were observed following ex vivo expansion (Supplemen-
tary Fig. 2), conﬁrming that dual-reactive T cells were a bona
ﬁde population and not an artifact of tetramer staining.
To gain additional molecular insight into the TCR clonotypes
present within each TL9-speciﬁc T cell population, we sequenced
Table 1 Demographic and clinical characteristics of the study participants
HLA B*81:01/B*42:01 B*81:01 B*42:01 (B*81:01 vs. B*42:01) P value
N 1 9 11 N/A
Female n (%) 1 (100%) 7 (77.8%) 10 (90.9%) 0.57b
Age (yr) 24 22.5 (22.25–28.5)a 22 (20.5–28.5)a 0.75c
CD4 counts, cells/mm3 1002 625 (495–802)a 588 (479–673)a 0.14c
Viral load, log10 2.11 3.38 (2.36–3.99)a 4.15 (3.40–4.84)a 0.03c
N/A not applicable
All values in parenthesis were expressed as interquartile range. Participants with other protective alleles present in the cohort of study were excluded in the study
Excluded alleles: HLA-B*57:03; B*58:01; B*39:01
aValues expressed as median (interquartile range)
bStatistical test used: Fisher’s exact test
cStatistical test used: Mann–Whitney test
Table 2 Detail class I HLA proﬁles of the study participants
Participants HLA-A HLA-B HLA-C
PT1 33:03/34:02 53:01/81:01 04:01/04:01
PT2 02:00/34:00 14:01/81:01 08:00/08:00
PT3 01:01/30:01 81:01/81:01 04:01/18:00
PT4 23:01/29:02 53:01/42:01 03:04/17:00
PT5 30:01/34:02 35:01/42:01 02:10/17:01
PT6 43:01/74:01 57:01/81:01 04:01/07:01
PT7 01:01/29:11 13:02/81:01 06:02/18:01
PT8 01:01/29:02 45:01/81:01 06:02/18:01
PT9 23:01/68:02 14:02/81:01 08:02/18:00
PT10 02:05/33:01 42:01/58:02 07:01/17:01
PT11 29:02/29:02 42:01/45:01 06:02/17:01
PT12 26:01/30:02 15:18/42:01 17:01/18:00
PT13 30:01/32:01 42:01/58:02 06:02/17:01
PT14 02:01/30:01 42:01/45:07 16:01/17:01
PT15 01:01/74:01 35:01/81:01 04:01/18:01
PT16 02:05/29:02 42:01/45:07 16:01/17:01
PT17 29:01/30:01 15:22/42:01 04:01/17:01
PT18 30:01/68:02 14:02/42:01 08:02/17:01
PT19 23:01/30:01 42:01/57:02 07:01/17:00
PT20 02:00/34:00 14:01/81:01 08:00/08:00
PT21 30:01/68:01 42:01/81:01 04:01/17:01
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the TCR β gene repertoire in single tetramer-labeled T cells
isolated by FACS from three B*81:01 and three B*42:01
expressing individuals who displayed mono- and dual-reactive
responses. Consistent with antibody staining results, Vβ gene
usage for mono- and dual-reactive B*81:01-derived populations,
as well as dual-reactive B*42:01-derived populations, was highly
restricted to TRBV12-3/12-4 (Fig. 3a, b). In contrast, while the
mono-reactive population in one B*42:01 expressing individual
(participant 11) was comprised largely of T cells encoding
TRBV12-3/12-4, the primary Vβ gene present in the other two
individuals (participants 13 and 17) was TRBV7-9 (Fig. 3b).
Notably, we observed that the dual-reactive population in all
three B*42:01 expressing individuals was dominated by four
public Vβ sequences (highlighted CDR3 regions in Fig. 3b) that
were never observed in B*81:01-derived TCR sequences. Enrich-
ment of TRBV12-3/12-4 usage by TL9-speciﬁc TCR in the context
of B*81:01 as well as the public dual-reactive TCR in B*42:01
expressing individuals suggested that features of these TCR
clonotypes contribute to control of HIV-1 infection.
Isolation and validation of TL9-speciﬁc TCR clones. To provide
a more complete understanding of mono- and dual-reactive CD8
+ T cell phenotypes, we identiﬁed the paired TCR α gene from
eight dominant TCR clones representing the mono- and dual-
reactive populations from B*81:01 and B*42:01 expressing indi-
viduals (Fig. 4a) and directly assessed TCR function using a
previously described in vitro reporter T cell assay56. Brieﬂy,
full-length TCR α/β genes were reconstructed and transiently
expressed in Jurkat T cells. TCR-mediated NFAT signaling was
quantiﬁed by luminescence following co-culture with HLA-
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Fig. 1 A dual TL9 tetramer+ response is associated with lower plasma viral load. A comparative analysis indicated lower plasma viral loads (log10)
among participants expressing B*81:01 compared to participants expressing B*42:01 (p= 0.03, Mann–Whitney U-test test) (a). Representative ﬂow plots
display TL9 tetramer responses observed in one B*81:01 expressing individual (top) and one B*42:01 expressing individual (bottom). A comparative
analysis of TL9 tetramer+ frequencies observed no difference between participants expressing B*81:01 compared to those expressing B*42:01 (p= 0.5;
Mann–Whitney U-test) (b). A comparative analysis of IFN-γ secretion following stimulation with TL9 peptide indicated a trend toward higher activity
among individuals expressing B*81:01 versus B*42:01 (p= 0.09, Mann–Whitney U-test) (c). Representative ﬂow plots display the dual TL9 tetramer-
reactive T cell population in B*81/42:01 expressing participant, one B*81:01 expressing participant and one B*42:01 expressing participant (d). A higher
proportion of B*81:01 expressing participants displayed dual-tetramer reactivity (p= 0.19, Chi-square test) (e). Multivariable linear regression
analyses that included HLA allele and presence of dual-tetramer reactive T cells as independent variables indicated that dual-reactivity (p= 0.02)
but not HLA (p= 0.23) was a signiﬁcant determinant of plasma viral load (f)
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used for TCR staining and sequencing could not distinguish
between TRBV12-3 and TRBV12-4, which differ by two amino
acids in the CDR1, TCR β genes were synthesized encoding both
alleles; however, only TRBV12-3 constructs were functional
(Supplementary Fig. 3). TCR clones displayed dose-dependent
responses to consensus TL9 over a range of peptide concentra-
tions (5 nM–20 µM) (Supplementary Fig. 4), indicating that the
reporter assay was sensitive and speciﬁc. Furthermore, recon-
structed TCR maintained mono- or dual-reactivity against TL9

























































































































































































































































































































































































































































































































































































































































































































































































































Fig. 2 Enrichment of TCR Vβ 12–3/12-4 in dual-reactive T cells. A representative ﬂow plot for one B*42:01 expressing individual displays mono- and dual-
TL9 tetramer reactive T cell populations and linked TCR Vβ expression proﬁles based on antibody staining (a). Aggregate results for TCR Vβ usage are
shown for mono- (blue) and dual-reactive (red) T cells from six B*81:01 expressing individuals (b) or six B*42:01 expressing individuals (c)
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expressing B*81:01 or B*42:01, conﬁrming that dual-reactive
T cells were a distinct population in both B*81:01 and B*42:01
expressing individuals, and that phenotypic differences in pHLA
speciﬁcity were due to TCR sequence.
Analyses of TL9 variant recognition by TCR clones. The ability
of TCR to cross-recognize epitope variants is associated with
enhanced antiviral activity of CD8+ T cells26,27,57. If indeed the
dual-reactive population contributes to control of HIV-1, we
hypothesized that it should be able to respond to a variety of TL9
variants. To explore this, we assessed the ability of each recon-
structed TCR to respond to a panel of 180 peptides representing
TL9 and all possible single amino acid TL9 variants. These results
are displayed as heat maps in Fig. 5 and also provided in the
Supplementary Data ﬁle. Collectively, the eight TCR clones
recognized 114 (of 171, 67%) TL9 variants at a normalized
luminescence value of 0.1 or greater (which was ~10-fold above
negative control wells). In addition to consensus TL9, individual
B*81:01-derived clones responded to 67 (11A10, mono-reactive),
53 (12A11, dual), and 94 (18A2, dual) variant peptides, while
B*42:01-derived clones responded to 48 (7A10, mono), 46
(13A10, mono), 54 (14A4, public dual), 34 (16A11, public dual),
and 34 (14D7, public dual) variant peptides. No correlation was
observed between the total breadth of TL9 variant recognition
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Fig. 3Molecular analysis of TCR β clonotypes in mono- and dual-reactive T cells. TCR β sequencing was performed on single FACS-sorted mono- and dual-
TL9 tetramer reactive T cells from three B*81:01 expressing participants (a) and three B*42:01 expressing participants (b). TRBV and CDR3 sequences were
determined using the IMGT V-quest tool (www.imgt.org). The total number of sequences collected per population is indicated under each pie chart.
Unique TCR β clones are displayed as wedges in the pie chart. The size of the wedge indicates the frequency of each sequence within the population and
the color represents TRBV usage. TCR β sequences in mono- and dual-reactive populations from B*81:01 expressing individuals were highly enriched for
TRBV12-3/12-4 usage (indicated in gray); however, no public sequences were observed among these individuals. Mono-reactive populations from B*42:01
expressing individuals encoded diverse TRBV and also lacked public sequences. In contrast, dual-reactive populations from B*42:01 expressing individuals
were enriched for TRBV12-3/12-4 usage (gray), and these sequences were comprised predominately of four identical (public) TCR β clones (highlighted by
colored boxes). Notably, these public clones were distinct from any TCR observed in B*81:01 individuals
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function contributed to this phenotype. The three TCR clones
isolated from B*81:01 expressing individuals (one mono- and two
dual-reactive) displayed similar overall TL9 variant cross-
recognition proﬁles, as demonstrated by Spearman R-values
>0.80 for all pair-wise associations; however, greater breadth
against variants at position 4 (aspartic acid) was seen for clone
18A2. In contrast, the ﬁve TCR clones isolated from B*42:01
expressing individuals displayed more disparate cross-recognition
proﬁles, which was reﬂected by pair-wise Spearman R-values
between 0.12 and 0.67. Notable differences were observed among
B*42:01-derived TCR clones for recognition of TL9 peptide var-
iants at positions 3 and 7, which are discussed below. To further


































































































































































































































































































































































































































Peptide pulsed HLA-B*81 traget cells Peptide pulsed HLA-B*42 traget cells
TCR ID Restriction TRAV TRAJ CDR3 Alpha TRBV TRBJ CDR3 Beta
b
c
Mono reactive B*42 7A10
Mono reactive B*81 TRC 11A10
Dual reactive B*42 14A4
Dual reactive B*42 14D7
Dual reactive B*42 16A11
Dual reactive B*81 12A11
Dual reactive B*81 TRC 18A2
Fig. 4 In vitro validation of TCR speciﬁcity and dual-reactivity. Details for the eight TL9-speciﬁc TCR clones investigated in this study are shown, including
donor HLA, mono- or dual-reactivity phenotype, paired TCR α/β V gene usage and CDR3 sequences (a). Jurkat T cells were co-transfected with TCR α/β,
CD8 α and an NFAT-driven luciferase reporter vector, and then co-cultured with TL9 peptide-pulsed (b) or HIV-infected (c) target cells stably expressing
B*81:01 or B*42:01. TCR-dependent NFAT signaling was quantiﬁed by luminescence. The expected mono- or dual-reactive phenotype was observed for all
reconstructed TCR clones, as indicated by greater luminescence (absolute light units, y-axis) in the presence of TL9-pulsed or virus-infected target cells
compared to no-peptide or uninfected controls. Assays were conducted at least three times. Results from a representative experiment are shown as the
mean of three co-culture reactions, plus standard deviation
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evaluate the degree of functional similarity among these TCR
clones, we performed a hierarchical clustering analysis based
on their TL9 variant recognition proﬁles. Results are shown
as a dendrogram in Fig. 5. We observed that all three of the
public dual-reactive B*42:01-derived clones grouped together
with bootstrap values of 100. Furthermore, this group of
public clones clustered more closely with the three B*81:01-
derived clones (bootstrap value of 97), compared to the two
mono-reactive B*42:01-derived clones. Together, these results
indicate that the epitope binding properties of the public dual-
reactive B*42:01-derived TCR clones are more similar to
those of clones elicited in the context of the more protective
B*81:01 allele, despite TL9 peptide being presented on a different
HLA allele.
Dual-reactive TCR recognize more TL9 escape mutations.
We observed substantial differences in TL9 variant recognition
among TCR clones, particularly at epitope positions 3 and 7.
To examine the impact of these differences on viral adaptation,
we restricted our analysis to 19 TL9 polymorphisms present
in circulating HIV-1 subtype C sequences at a prevalence of
~0.1% or greater, which were considered as viable escape muta-
tions. The ability of each TCR to recognize this panel of mutants
is illustrated as a SequenceLogo in Fig. 6a–h. Collectively,
the eight TCR clones recognized 16 (of 19, 84%) TL9 escape
mutants; none responded to a threonine, glycine or aspartic
acid substitution at position 3, which together accounted for
26.1% of circulating variant sequences. These results were highly
consistent with prior studies of T cell cross-reactivity based on
IFN-γ ELISPOT assays using PBMC40,41,43, with 7 (of 8; 88%)
TCR clones recognizing serine at position 7 or alanine at position
3, whereas responsiveness to other natural polymorphisms at
position 3 (histidine, 13%; serine, 13%; threonine, 0%) and
position 7 (valine, 75%; methionine, 25%) were less common.
While the total number of TL9 escape mutants recognized
by B*81:01-derived TCR clones (range, 8–14), public dual-
reactive B*42:01-derived clones (6–9), and mono-reactive
B*42:01-derived clones (6–7) was not signiﬁcantly different
between groups, we observed that the two mono-reactive
B*42:01-derived TCR clones responded primarily to variants
located at either position 7 (for 7A10) (Fig. 6a) or position 3 (for
13A10) (Fig. 6b), indicating a limited ability to control escape
mutations that occur at the other residue. In contrast, B*81:01-
derived TCR clones and public dual-reactive B*42:01-derived
clones each displayed broader recognition of variants at both
position 3 and 7 (Fig. 6c–h), suggesting a distinct mechanism(s)
of binding that accommodated changes at these residues.
B*81:01-derived TCR clones also displayed broader recognition of
TL9 variants at position 5. These results demonstrate functional
differences among TCR clonotypes that may contribute to control
of naturally occurring TL9 variants, particularly at epitope posi-
tions 3 and 7.
HIV-1 adaptation to CD8+ T cells is highly dynamic58,59, but
escape in TL9 is limited by functional constraints44. Since
common TL9 variants, such as serine at position 7 (S7; 23.4% of
non-consensus sequences in LANL), are presumed to encounter a
relatively lower barrier to escape compared to rare variants, such
as isoleucine at this position (I7: 0.7%), we reasoned that TCR
recognition of more common TL9 variants would be beneﬁcial
for viral control. To explore this, we plotted these 19 TL9
polymorphisms using pie charts with wedges sized according to
their prevalence in subtype C sequences (Fig. 6i–p) and then
determined the percent coverage of TL9 escape mutations for
each TCR by calculating the proportion of total sequence
variation that was recognized (see wedges highlighted in Red).
Based on this frequency-adjusted analysis, individual clones
displayed 22% (Fig. 6j) to 67% (Fig. 6p) coverage of TL9 variants.
While differences between groups were not statistically signiﬁ-
cant, B*81:01-derived TCR clones and public dual-reactive
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Fig. 5 Functional clustering of TCR clones based on TL9 variant recognition proﬁles. TCR recognition of TL9 variants was assessed by pulsing target cells
expressing the donor HLA (B*81:01 or B*42:01) with a panel of 180 peptides encompassing all single amino acid substitutions at epitope positions 1 through
9 prior to co-culture with Jurkat T cells expressing the TCR of interest. TCR-dependent NFAT signaling was quantiﬁed by luminescence. Values were
normalized to the mean signal obtained for consensus TL9 (set to 1.0), which was tested nine times in each experiment. Results are displayed as heatmaps,
where the warmer color reﬂects higher relative luminescence values indicative of better TCR recognition. Peptide positions are shown at the top of each
heatmap; amino acid substitutions on the consensus TL9 backbone are shown on the left-hand side. Amino acids are grouped according to chemical
properties: polar residues (G, S, T, Y, C, Q, N) are highlighted in green; basic residues (K, R, H) are blue; acidic residues (D, E) are red; and hydrophobic
residues (A, V, L, I, P, W, F, M) are black. For reference, the consensus TL9 residue at each position is indicated using a box. TCR were grouped according
to their functional proﬁles by hierarchical clustering using correlation distances and single linkage methods (5000 iterations) implemented in pvclust
(http://stat.sys.i.kyoto-u.ac.jp/ prog/pvclust/). The dendrogram (top) displays approximately unbiased (au) p-values in red text and bootstrap
probability (bp) values in green text. The three B*81:01-derived TCR clustered with bp values of 93 or higher. The three public dual-reactive B*42:01-
derived TCR clustered with bp values of 100; and, notably, they grouped more closely with B*81:01 clones (bp value of 97), rather than mono-reactive
B*42:01-derived TCR
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B*42:01 clones tended to display greater coverage (40–67% and
36–41%, respectively) compared to the mono-reactive B*42:01
clones (22 and 32%). These results indicate that individual TCR
clonotypes display variable capacity to recognize more common
TL9 variants that are likely to constitute preferential escape
mutants.
Since codon usage places additional constraints on viral
sequence evolution, we reasoned that TCR recognition of
transitional variants would hinder the development of TL9
escape. For example, substitution of glutamine at position 3 (Q3)
with serine (S3) requires a minimum of two nucleotide changes
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recognition of the P3 variant would be expected to prevent
formation of S3, even in cases where the TCR did not respond
to the S3 variant itself. For each TCR clone, we determined
which TL9 escape mutations were inhibited due to recognition
of critical transitional variants (see yellow wedges in Fig. 6i–p).
We then calculated the total coverage of TL9 escape pathways
by summing the proportion of variant sequences that were
recognized or prevented by each TCR (i.e., red plus yellow
wedges). Based on this pathway-adjusted analysis, individual
TCR clones displayed 32–83% coverage of TL9 escape mechan-
isms. Notably, B*81:01-derived clones (range, 57–83%, Fig. 6n–p)
and public dual-reactive B*42:01-derived clones (range, 52–83%,
Fig. 6k–m) displayed broader coverage compared to mono-
reactive B*42:01-derived clones (both 32%, Figs. 6i–j) (p= 0.05
and p= 0.11, respectively; Student’s T test); highlighted by
one public dual-reactive B*42:01-derived clone (14A4) and
one B*81:01-derived clone (18A2). Notably, extended coverage
of TL9 escape pathways was due mainly to the ability of
TCR clones 14A4 (K), 14D7 (L), 16A11 (M), 11A10 (N), and
12A11 (O) to respond to the P3 variant, which is anticipated
to impair development of the S3 escape mutation that accounts
for 16.5% of TL9 variant sequences. Together, these results
illustrate the functional diversity that exists among antigen-
speciﬁc T cells and demonstrate the impact of TCR sequence
on recognition of HIV-1 Gag TL9 escape mutations. This work
highlights the role of TCR clonotype differences as a correlate of
HIV-1 control in the context of HLA B*81:01 and B*42:01.
Discussion
The characteristics that determine effectiveness of adaptive
host immune responses to rapidly evolving pathogens such as
HIV-1 are not fully deﬁned. In this study, we examined the CD8+
T cell response against the immunodominant HIV-1 p24
Gag TL9 epitope in the context of two closely related class I
HLA alleles, B*81:01 and B*42:01, that display differential
abilities to control viral subtype C infection9. We identiﬁed a
population of dual HLA tetramer-reactive T cells that recognized
TL9 presented in the context of either B*42:01 or B*81:01 alleles
and observed that the presence of this dual-reactive population
was an independent predictor of lower plasma viral load.
In B*42:01 expressing individuals, dual-reactive populations
were dominated by public TCR clonotypes that encoded
TRBV12-3. A comprehensive in vitro functional analysis of
selected TCR clones indicated that B*81:01-derived clones
(regardless of mono- or dual-reactive phenotype) and public
dual-reactive B*42:01-derived TCR clones displayed greater
ability to recognize TL9 escape pathways, compared to mono-
reactive clones from B*42:01 expressing individuals. While the
dual-reactive T cell phenotype reported here is a phenomenon of
tetramer binding to pHLA that is not expressed by the host, our
results indicate that it identiﬁes T cell subsets within diverse
antigen-speciﬁc repertoires that share important features,
including Vβ gene sequences and the ability to recognize HIV-1
epitope variants. A similar dual HLA-reactive phenotype has been
described for one CTL clone51, but here we demonstrate the
extent to which dual-reactive T cells exist in vivo and link this
phenotype to functional characteristics of individual TCR clo-
notypes. It will be critical to examine this phenomenon further to
see if it is a common feature of T cell responses elicited in the
context of other HLA supertypes, such as members of the B57
family that also show differential abilities to control HIV-1
infection9.
It is important to note that antigen sensitivity appeared to
be independent of cross-reactivity for TCR examined in this
study. While more detailed biochemical analyses will be
necessary to fully assess the afﬁnity of TL9-speciﬁc TCR clones,
our reporter assay provides a surrogate measure of antigen
sensitivity based on strength of NFAT signaling. The activities
of dual-reactive B*42:01-derived TCR clones were lower com-
pared to those of mono-reactive B*42:01-derived clones. We
observed similar differences in the sensitivity of representative
TCR clones tested over a range of TL9 concentrations (Supple-
mentary Fig. 3), indicating that this result was not an artifact of
peptide dose. In addition, TCR sensitivity toward consensus TL9
did not correlate with cross-recognition of TL9 variants in our
more comprehensive analysis, although it will be important
to conﬁrm this observation using a larger panel of TL9-speciﬁc
TCR clones.
Although B*81:01 and B*42:01 are both members of the
B7 supertype and known to present many of the same HIV-1
peptides, the dual-reactive T cell phenotype is unexpected since
structural data indicated that TL9 adopts a distinct conformation
upon binding to each allele45. Our analysis demonstrated that
B*81:01-derived TCR clones and public dual-reactive B*42:01-
derived clones recognized TL9 variants at both principal sites of
viral escape, positions 3 and 7. This is interesting since both
residues are buried in the B*81:01 structure, while position 7 is
solvent-exposed in the context of B*42:0145. It remains to be
determined whether TCR recognition reﬂects direct binding to
these TL9 variants, or rather is due to conformational changes in
the pHLA or indirect effects on other TL9 residues. In contrast,
mono-reactive B*42:01-derived TCR displayed breadth against
TL9 variants at either position 3 or position 7, but not both.
While both types of mono-reactive TCR may be present within
the repertoire of B*42:01 expressing individuals, skewing of the
Fig. 6 Enhanced recognition of TL9 escape by B*81:01-derived and B*42:01-derived dual-reactive TCR clones. The ability of each TCR clone to respond to
HIV-1 escape mutants was determined by comparing its recognition proﬁle to a panel of 19 naturally occurring subtype C TL9 variants, found at a
prevalence of ~0.1% or greater in the LANL HIV Sequence Database (HIV Databases; http://www.hiv.lanl.gov). Recognition breadth for each TCR is
illustrated as a SequenceLogo, demonstrating variable responsiveness toward relevant TL9 mutations located primarily at epitope positions 3 and 7. Mono-
reactive TCR from B*42:01 expressing individuals displayed narrower proﬁles that recognized TL9 variants at either position 7 (7A10, a) or position 3
(13A10, b), whereas public dual-reactive B*42:01-derived clones (c–e) and B*81:01-derived clones (f–h) demonstrated broader ability to recognize TL9
variants at both positions 3 and 7. To account for constraints on TL9 escape, epitope variants were displayed using pie charts where the size of each wedge
is proportional to variant frequency in circulating subtype C isolates (i–p). Serine at position 7 (S7), serine at position 3 (S3), and threonine at position 3
(T3) accounted for the majority (55%) of population-level variation. For each chart, the wedge is shaded in red (R) if the TCR responded to the escape
mutant or in yellow (Y) if the TCR recognized all transitional mutations required to generate that escape mutant from consensus TL9. The sum of all
red wedges is displayed under each chart as the total percentage of Variant Epitope Recognition and the sum of all shaded wedges, red plus yellow, is
displayed as the total percentage of Escape Pathway Recognition, where recognition of all circulating TL9 variants would be 100%. Overall, B*81:01-derived
TCR (n–p) and public dual-reactive B*42:01-derived TCR (k–m) displayed better ability to cross-recognize circulating TL9 escape variants and pathways
compared to mono-reactive B*42:01-derived clones (i–j)
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immune response toward either mono-reactive TCR subset could
facilitate viral escape at the alternative TL9 position.
Our detailed functional data provides insight into character-
istics of TL9-speciﬁc TCR clones that might be overlooked using
more conventional methods based on HIV-1 sequences alone. For
example, all TCR clones were sensitive to changes at TL9 position
6, demonstrating that this highly conserved polar asparagine
residue is critical in the context of both HLA alleles, despite it
being solvent-exposed in the B*81:01 structure and buried in the
B*42:01 structure45. In addition, most TCR were sensitive to
changes at position 4, indicating that this negatively charged,
polar aspartic acid residue (which is solvent-exposed in both
structures45) is critical for recognition; however, the B*81:01-
derived clone 18A2 tolerated mutations at this residue, suggesting
a distinct mechanism of interaction in this case. Structural ﬂex-
ibility is a crucial feature of the interaction between TCR and
pHLA;60–62 thus, changes in conformation induced upon TCR
binding may be relevant to recognize TL9 variants in the context
of both B*81:01 and B*42:01. Because such conformational
rearrangements are difﬁcult to predict63, more detailed structural
analyses will be necessary to explore this issue. In the absence of
such data, we are unable to deﬁne structural determinants of
cross-reactivity for the TCR clones examined in our study.
Nevertheless, our results highlight peptide-recognition properties
that may contribute to future studies of these and other TL9-
speciﬁc TCR.
This work extends prior efforts to examine TL9-speciﬁc CD8+
T cell responses. In particular, Leslie et al.40 and Geldmacher
et al.41 observed enrichment of TRBV12-3 usage in B*81:01 and
some B*42:01 expressing individuals, while Leslie et al.40 and
Kloverpris et al.34 described public TCR β sequences in B*42:01
expressing individuals that correspond to the dual-reactive TCR
clones 14A4 (CASSFSKNTEAFF) and 14D7 (CASSHSKN-
TEAFF) examined here and demonstrated that the presence of
these public clones was associated with TL9 immunodomi-
nance34. These earlier reports suggested that CD8+ T cell
responses in B*81:01 expressing individuals displayed broader
recognition of TL9 variants, but individual T cell clones (or TCR
clonotypes) were not explored. Here, we re-discovered public
TCR β clonotypes in B*42:01 expressing individuals by their dual
HLA-reactive phenotypes. Extensive functional analyses of
selected TCR clones demonstrated substantial diversity in their
abilities to recognize TL9 variants. Our results emphasize the role
of cross-reactive public TCR clones encoding TRBV12-3 for
effective TL9 responses in B*42:01 expressing individuals; how-
ever, differences in TL9 variant recognition among these public
clones also suggests a functional hierarchy that may be clinically
relevant. Furthermore, it should be noted that B*42:01-derived
clone 7A10 encoded TRBV12-3 but did not demonstrate dual-
reactivity or broad recognition of TL9 escape variants, indicating
that phenotypic differences among TCR were not driven entirely
by V gene usage.
Several observations from this study are relevant for the design
of vaccines or therapeutics. Vaccine antigens that can elicit
effective cross-reactive TCR clonotypes might provide better
protection against HIV-1 infection or enhance the ability of the
immune system to recognize latent viral reservoirs encoding
escape variants. We observed that public dual-reactive TCR
clones from B*42:01 expressing individuals were unique in their
ability to recognize a proline variant at TL9 position 3 (Q3P). It
would be interesting to examine ex vivo responses to this rare TL9
variant as a surrogate marker for public dual-reactive T cells
HIV-infected individuals or vaccine recipients; or to consider
vaccination with this variant TL9 sequence to elicit a more
broadly reactive T cell response in B*42:01 expressing individuals.
We have also identiﬁed and validated the recognition proﬁles of
eight TL9-speciﬁc TCR clones, including several with dual HLA-
reactive phenotypes. These TCR clones may be attractive pro-
ducts for future T cell therapy strategies that aim to reduce or
eliminate viral reservoirs encoding escape mutations in the con-
text of HIV-1 subtype C infection.
In summary, we have identiﬁed characteristics of TCR clono-
type sequence and function that are associated with variable
control of HIV-1 infection in the context of B*81:01 and B*42:01.
We observed a unique dual HLA-reactive CD8+ T cell population
that was highly enriched for a small number of public TCR clo-
notypes in B*42:01 expressing individuals. Mono- and dual-
reactive TCR clones from individuals expressing the protective
B*81:01 allele displayed broad recognition of TL9 variants, sug-
gesting that they provide comparable abilities to contain HIV-1
Gag escape mutants. In contrast, only public dual-reactive TCR
clones from B*42:01 expressing individuals displayed similar
broad TL9 variant recognition, suggesting that these public clo-
notypes provide enhanced ability to control HIV-1 escape
mutants in the context of this less protective HLA allele. While
additional studies will be necessary to fully assess the structural
mechanisms and clinical relevance of these observations, this
work provides a strong foundation and rationale to further
explore the impact of TCR clonotype differences on HIV-1 out-
comes. Together, our results highlight the feasibility and use of
detailed molecular analyses that link TCR sequences with func-
tional characteristics to improve understanding of T cell
responses against diverse and rapidly evolving pathogens. Similar
investigations might be beneﬁcial to enhance the development of
vaccines and T cell-based immunotherapies against HIV or other
human diseases.
Methods
Study subjects. Twenty-one antiretroviral naive individuals were enrolled in
Durban, South Africa through the HIV Pathogenesis Program (HPP) acute
infection cohorts. The clinical characteristics are shown in Table 1. All individuals
were infected with HIV-1 subtype C. The Biomedical Research Ethics
Committee of the University of KwaZulu-Natal and the Massachusetts General
Hospital Ethics committee approved this study. All subjects provided written
informed consent.
HLA typing. HLA typing was conducted by the laboratory of Dr. Mary Carrington
(National Cancer Institute, Fredrick, USA), as previously described9. DNA
samples obtained from peripheral blood mononuclear cells (PBMC) were ﬁrst
oligo-typed using Dynal RELITM reverse Sequence Speciﬁc Oligonucleotide
(SSO) kits for the HLA-A, HLA-B, and HLA-C loci (Dynal Biotech). Genotypes
were reﬁned to the allelic level using the Dynal Biotech Sequence Speciﬁc
priming (SSP) kits in conjunction with the previous SSO type. In cases where
alleles were still not well-deﬁned at the allelic level, sequence-speciﬁc primers
were used64. All class I HLA alleles in the IMGT allele release 24.0 were considered
in the typing.
Tetramer staining, cell sorting, and cell line generation. To identify and
characterize TL9-speciﬁc CD8+ T cell populations, PBMC were ﬁrst stained
with a cell-viability dye (Fixable Blue Dead Cell Stain Kit, Invitrogen) for 10 min
at room temperature. Cells were washed with 2% fetal calf serum (FCS) in
phosphate buffered saline (PBS) and then stained with B*42:01-APC and/or
B*81:01-PE TL9 HLA class I tetramers (obtained from the laboratory of Dr. Soren
Buus), for 30 min at room temperature. Subsequently, cells were washed, and
surface stained with anti-CD8-BV786, CD3-BV711, and CD4-BV650 for 20 min
at room temperature. Stained cells were analyzed by ﬂow cytometry and/or
tetramer-speciﬁc CD8+ T-cells were sorted for TCR sequencing. To generate TL9-
speciﬁc CD8+ T-cell lines, cells were pulsed with 5 µl (200 µg ml−1) of TL9
peptide at 37 °C for 3 h and subsequently cultured in RPMI medium contain-
ing 10% heat-inactivated fetal calf serum (R10 medium) supplemented with
50 units ml−1 of recombinant human interleukin 2 (IL-2) (R10/50 medium)
for 2 weeks. Expanded TL9-speciﬁc CD8+ T cells were validated for
speciﬁcity by tetramer staining and isolated using a cell sorter (BD FACSAria,
Germany).
Tetramer intracellular cytokine staining and ELISPOT assay. To assess the
functional quality of TL9-speciﬁc CD8+ T cells, PBMC from B*81:01 and
B*42:01 subjects were stimulated with 1.2 µl (200 µg ml−1) of TL9 peptide for 6 h.
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After stimulation, cells were stained with an equal mixture of B*81:01 and B*42:01
TL9 tetramers for 30 min at room temperature, washed in PBS containing 2% FCS
and then stained with viability dye, anti-CD8-BV786, CD3-BV711, and CD4-
BV650 for 20 min at room temperature. Cells were ﬁxed, permeabilized, stained
intracellularly with anti-IFN-γ-PE-Cy7 and analyzed on the BD LSRFortessa. HIV-
1 immune responses were enumerated by IFN-γ enzyme-linked immunosorbent
spot (ELISPOT) assay as previously described9,65. Brieﬂy, PBMCs were stimulated
with optimal HIV-1 subtype C peptide corresponding to each patient’s HLA-A, B,
and C alleles at a ﬁnal concentration of 2 μg ml−1 peptide.
TCR Vβ antibody staining. TCR variable β (Vβ) expression on mono- and dual-
tetramer+ cells was assessed by ﬂow cytometry as described previously66. PBMC
were stained with B*81:01 and/or B*42:01 TL9 tetramers conjugated to different
ﬂuorochromes, followed by TCR Vβ family labeling using IOTest Beta Mark TCR
Vβ repertoire kit (Beckman Coulter, Pasadena, USA) for 30 min at room tem-
perature. Subsequently, cells were stained with viability dye, anti-CD8-BV786,
CD3-BV711, and CD4-BV650. The percentage of each Vβ family was determined
for a minimum of 100,000 CD8+ T cells using FlowJo software (Treestar, Ashland,
USA). TCR Vβ staining was also performed on expanded mono- and dual-TL9
tetramer+ cell lines.
TCR sequencing. Ampliﬁcation of TCR β CDR3 coding regions from single T cells
was performed as described previously by Han et al.67 with modiﬁcations to obtain
~230 bp amplicons for Sanger sequencing (ABI 3130xl). Primers are included in
Supplementary Tables 2 and 3. The one-step SuperScript III kit (ThermoFisher)
was used for RT-PCR and Expand High Fidelity PCR system (Roche) was used for
subsequent rounds. TCR α amplicons were TOPO cloned and screened to ensure
productive CDR3 rearrangement. Sequences were examined using the ImMuno-
GeneTics (IMGT)/V-quest tool (www.imgt.org) to characterize Variable gene
usage and CDR3 diversity. Full-length TCR alleles were reconstructed using
Variable and Constant gene sequences obtained from the IMGT database, codon-
optimized using the CodonOpt tool (Integrated DNA Technologies; www.idtdna.
com) and synthesized as double-stranded DNA gBlocks by IDT. Full-length genes
were cloned into pSELECT_GFPzeo (Invivogen) for functional studies.
TCR reporter assay. TCR antigen recognition was examined using a previously
described in vitro reporter T cell assay56. Brieﬂy, Jurkat T cells were co-transfected
with TCR α, TCR β, CD8 α, and NFAT-driven luciferase reporter plasmids by
electroporation (BioRad MxCell). Target cells consisted of a CEM-derived GXR cell
line68 stably expressing either HLA-B*42:01 or B*81:01. TCR-transfected Jurkat
effector cells (50,000 cells) were co-cultured with 50,000 target cells either pulsed
with 20 µM TL9 peptide (purchased from GenScript at >90% purity) or infected
with HIV-1 in a total volume of 100 µl, and TCR recognition activity was quan-
tiﬁed by luminescence after 6 h (Tecan M200). Viral stocks were generated by co-
transfection of HEK293T cells with pBR4.3ΔNefΔEnv and pVSV-g using Lipo-
fectamine 2000 (ThermoFisher Scientiﬁc). Infected GXR target cells were isolated
by FACS based on GFP expression prior to co-culture with Jurkat T cells. To screen
antigen cross-recognition, a peptide panel consisting of all single amino acid TL9
variants (180 total peptides) was purchased from GenScript. This panel was pre-
pared using microscale synthesis methods and individual peptides were aliquoted
to 96-well plates at 0.5–2.0 mg total weight and >75% purity. Target cells were
pulsed with ~20 µM peptide; however, due to variations in peptide sequence, total
weight, molar weights and purity, actual concentrations were anticipated to range
between 8.4 and 20 µM.
HIV sequence analysis. To determine the frequency of naturally occurring Gag
TL9 variants in HIV-1 subtype C infection, all subtype C TL9 amino acid
sequences (N= 5481) were downloaded from the Los Alamos National Laboratory
(LANL) HIV sequence database (www.hiv.lanl.gov) and analyzed. Sequences
encoding consensus TL9 (N= 4526), multiple substitutions or mixed residues
(combined N= 217) and those appearing fewer than ﬁve times (N= 53) were
removed to generate a list of the most probable single amino acid TL9 variants (N
= 685). The proportion of each variant within this population was calculated to
determine the likelihood of viral escape. Critical transition mutations (i.e., those
that must to occur for consensus TL9 to evolve into escape variants) were identiﬁed
using the standard amino acid codon table for eukaryotes. Sequence conservation
frequencies for TL9 residues were estimated using the QuickAlign tool on the
LANL web site (based on N= 1865 protein sequences).
Statistical analysis. Statistical analyses were conducted using Prism software,
version 6.0 (GraphPad, Inc.). Two-tailed tests were employed, and p-values <0.05
were considered to be signiﬁcant. Comparisons between groups of continuous
variables were assessed using parametric (unpaired Student’s T) or non-parametric
(Mann–Whitney U) tests. Differences in categorical variables between groups were
assessed using Fisher’s exact test. A multivariable linear regression analyses was
conducted using Stata, version 14 (Stata Corp), to assess the independent predictive
ability of HLA and dual-reactivity on plasma viral loads. Hierarchical clustering
analysis was performed using pvclust software69 (http://stat.sys.i.kyoto-u.ac.jp/
prog/pvclust), implemented in R. Data was grouped according to correlation
distances using single linkage methods. Approximately unbiased (au) p-values and
bootstrap probability (bp) values were based on 5000 iterations.
Data availability
Participants specimens, primary cell data, reagents for TCR sequencing and
reporter cell assays used for peptide screening are available from the corresponding
authors on reasonable request. Contact Zaza M. Ndhlovu (zndhlovu@mgh.harvard.
edu) with requests regarding reagents and resource sharing for participant speci-
mens, sequences and primary cell data. Similar requests regarding TCR sequencing
and reporter cell assays used for peptide screening should be directed toward Mark
A. Brockman (mark_brockman@sfu.ca). Paired TCR sequences are available
through Genbank, accession codes: [MH918759-MH918774].
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